TY  - GEN
AU  - Younes,Anas
AU  - Sehn,Laurie H
AU  - Johnson,Peter
AU  - Zinzani,Pier Luigi
AU  - Hong,Xiaonan
AU  - Zhu,Jun
AU  - Patti,Caterina
AU  - Belada,David
AU  - Samoilova,Olga
AU  - Suh,Cheolwon
AU  - Leppä,Sirpa
AU  - Rai,Shinya
AU  - Turgut,Mehmet
AU  - Jurczak,Wojciech
AU  - Cheung,Matthew C
AU  - Gurion,Ronit
AU  - Yeh,Su-Peng
AU  - Lopez-Hernandez,Andres
AU  - Dührsen,Ulrich
AU  - Thieblemont,Catherine
AU  - Chiattone,Carlos Sergio
AU  - Balasubramanian,Sriram
AU  - Carey,Jodi
AU  - Liu,Grace
AU  - Shreeve,S Martin
AU  - Sun,Steven
AU  - Zhuang,Sen Hong
AU  - Vermeulen,Jessica
AU  - Staudt,Louis M
AU  - Wilson,Wyndham
TI  - Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
SN  - 1527-7755
PY  - 2020///0408
KW  - Adenine
KW  - analogs & derivatives
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Cyclophosphamide
KW  - Double-Blind Method
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Piperidines
KW  - Placebos
KW  - Prednisone
KW  - Progression-Free Survival
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Rituximab
KW  - Survival Rate
KW  - Vincristine
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.18.02403
ER  -